Post-earnings recap
Reported
Tue, Nov 10, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a loss per share of $0.28, which was below expectations. The stock reacted negatively, declining by 1.88%. The lack of revenue figures and guidance may contribute to investor uncertainty moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.28 | N/A | -27.27% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based solely on numerical results.